COVID-19 vaccine intention among young adults: Comparative results from a cross-sectional study in Canada and France.
COVID-19
Preventive measures
Vaccination
Young adults
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
06 04 2022
06 04 2022
Historique:
received:
06
08
2021
revised:
03
02
2022
accepted:
28
02
2022
pubmed:
21
3
2022
medline:
6
4
2022
entrez:
20
3
2022
Statut:
ppublish
Résumé
High rates of COVID-19 vaccination uptake are required to attain community immunity. This study aims to identify factors associated with COVID-19 vaccine uncertainty and refusal among young adults, an underexplored population with regards to vaccine intention generally, in two high-income settings: Canada and France. A cross-sectional online survey was conducted from October to December 2020 among young adults ages 18-29 years (n = 6663) living in Canada (51.9%) and France (48.1%). Multinomial logistic regression analyses were performed to identify the sociodemographic and COVID-19-related measures (e.g., prevention behavior and perspectives, health-related concerns) associated with vaccine uncertainty and refusal. We conducted weighted analyses by age, gender and province/region of residence. Intention to accept vaccination was reported by 84.3% and 59.7% of the sample in Canada and France, respectively. Higher levels of vaccine uncertainty and refusal were observed in France compared to Canada (30.1% versus 11%, 10.2% versus 4.7%). In both countries, we found higher levels of vaccine acceptance among young adults who reported COVID-19 prevention actions. Vaccine uncertainty and refusal were associated with living in a rural area, having lower levels of educational attainment, not looking for information about COVID-19, not wearing a face mask, and reporting a lower level of concern for COVID-19's impact on family. Participants who had been tested for COVID-19 were less likely to intend to refuse a vaccine. COVID-19 vaccine acceptance was high among young adults in Canada and France during a time in which vaccines were approved for use. Targeted interventions to build confidence in demographic groups with greater hesitance (e.g., rural and with less personal experience with COVID-19) may further boost acceptance and improve equity as vaccine efforts continue to unfold.
Sections du résumé
BACKGROUND
High rates of COVID-19 vaccination uptake are required to attain community immunity. This study aims to identify factors associated with COVID-19 vaccine uncertainty and refusal among young adults, an underexplored population with regards to vaccine intention generally, in two high-income settings: Canada and France.
METHODS
A cross-sectional online survey was conducted from October to December 2020 among young adults ages 18-29 years (n = 6663) living in Canada (51.9%) and France (48.1%). Multinomial logistic regression analyses were performed to identify the sociodemographic and COVID-19-related measures (e.g., prevention behavior and perspectives, health-related concerns) associated with vaccine uncertainty and refusal. We conducted weighted analyses by age, gender and province/region of residence.
RESULTS
Intention to accept vaccination was reported by 84.3% and 59.7% of the sample in Canada and France, respectively. Higher levels of vaccine uncertainty and refusal were observed in France compared to Canada (30.1% versus 11%, 10.2% versus 4.7%). In both countries, we found higher levels of vaccine acceptance among young adults who reported COVID-19 prevention actions. Vaccine uncertainty and refusal were associated with living in a rural area, having lower levels of educational attainment, not looking for information about COVID-19, not wearing a face mask, and reporting a lower level of concern for COVID-19's impact on family. Participants who had been tested for COVID-19 were less likely to intend to refuse a vaccine.
CONCLUSIONS
COVID-19 vaccine acceptance was high among young adults in Canada and France during a time in which vaccines were approved for use. Targeted interventions to build confidence in demographic groups with greater hesitance (e.g., rural and with less personal experience with COVID-19) may further boost acceptance and improve equity as vaccine efforts continue to unfold.
Identifiants
pubmed: 35305823
pii: S0264-410X(22)00260-2
doi: 10.1016/j.vaccine.2022.02.085
pmc: PMC8890971
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2442-2456Subventions
Organisme : CIHR
ID : VR5 172673
Pays : Canada
Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Vaccines (Basel). 2021 Jan 20;9(2):
pubmed: 33498282
J Community Health. 2021 Apr;46(2):270-277
pubmed: 33389421
Eur J Epidemiol. 2020 Aug;35(8):781-783
pubmed: 32761440
Euro Surveill. 2020 Dec;25(50):
pubmed: 33334399
EBioMedicine. 2016 Oct;12:295-301
pubmed: 27658738
PLoS One. 2021 Apr 16;16(4):e0250123
pubmed: 33861765
Nat Commun. 2021 Jan 4;12(1):29
pubmed: 33397962
Lancet Public Health. 2021 Apr;6(4):e210-e221
pubmed: 33556325
Proc Natl Acad Sci U S A. 2020 Nov 3;117(44):27285-27291
pubmed: 33060298
Ann Intern Med. 2020 Dec 15;173(12):964-973
pubmed: 32886525
J Public Health (Oxf). 2021 Sep 22;43(3):445-449
pubmed: 33367857
Nat Hum Behav. 2021 Mar;5(3):337-348
pubmed: 33547453
Vaccine. 2008 Oct 9;26(43):5484-93
pubmed: 18703109
Euro Surveill. 2013 Oct 31;18(44):
pubmed: 24176658
Expert Rev Vaccines. 2016 Jul;15(7):937-48
pubmed: 27140417
EBioMedicine. 2015 Jun 23;2(8):891-7
pubmed: 26425696
BMJ Open. 2021 Aug 2;11(8):e048025
pubmed: 34341047
Vaccines (Basel). 2020 Dec 30;9(1):
pubmed: 33396832
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Nat Immunol. 2019 Oct;20(10):1257-1259
pubmed: 31477920
PLoS One. 2016 Jun 03;11(6):e0156118
pubmed: 27257809
Vaccines (Basel). 2021 Feb 05;9(2):
pubmed: 33562872
Nat Med. 2021 Feb;27(2):225-228
pubmed: 33082575
PLoS Curr. 2015 Feb 25;7:
pubmed: 25789201
Psychol Med. 2020 Oct 19;:1-3
pubmed: 33070804
Front Psychol. 2020 Oct 19;11:575950
pubmed: 33192883
Vaccine. 2015 Aug 14;33(34):4161-4
pubmed: 25896383
Euro Surveill. 2021 Jan;26(3):
pubmed: 33478623
J Prev (2022). 2022 Feb;43(1):83-93
pubmed: 34797468
J Am Coll Health. 2022 Apr 15;:1-10
pubmed: 35427458
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Lancet. 2020 Sep 26;396(10255):898-908
pubmed: 32919524
Am J Health Promot. 2022 Jan;36(1):175-179
pubmed: 34164998
Vaccine. 2022 Jan 21;40(2):178-182
pubmed: 34863619
Death Stud. 2020;44(7):393-401
pubmed: 32299304
Elife. 2021 Apr 08;10:
pubmed: 33830018
Eur J Health Econ. 2020 Sep;21(7):977-982
pubmed: 32591957
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Vaccine. 2021 Jul 5;39(30):4027-4028
pubmed: 34120767
Annu Rev Public Health. 2021 Apr 1;42:175-191
pubmed: 33798403
Vaccine. 2018 Jan 25;36(4):545-552
pubmed: 29233605